Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: An INITIO substudy

Clinical and Experimental Immunology

Volumn 152, Issue 2, 2008, Pages 252-257

  Burton, C T ^a   Goodall, R L ^b   Samri, A ^c   Autran, B ^c   Kelleher, A D ^d   Poli, G ^e   Pantaleo, G ^f   Gotch, F M ^a   Imami, N ^a,g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HAART; HIV 1; NNRTI; PI; Tetanus toxoid

Indexed keywords

DIDANOSINE; EFAVIRENZ; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; TETANUS TOXOID;

ADD ON THERAPY; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; TETANUS TOXOID; VIRAL LOAD;

EID: 42049096368     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03611.x     Document Type: Article

References (23)

1. INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, Aboulker JP et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006 368 : 287 98.
2. Samri A, Goodall R, Burton C et al. Durable long-term immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease. Antivir Ther 2007 12 : 553 8.
3. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006 7 : 487 503.
4. Pozniak A, Gazzard B, Anderson J et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003 4 (Suppl. 1 1 41.
5. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005 6 (Suppl. 2 1 61.
6. Galbraith NS, Forbes P, Tillett H. National surveillance of tetanus in England and Wales 1930-79. J Infect 1981 3 : 181 91.
7. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997 278 : 1447 50.
8. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 338 : 853 60.
9. Pakker NG, Notermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998 4 : 208 14.
10. Pakker NG, Roos MT, van Leeuwen LR et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997 16 : 318 26.
11. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997 277 : 112 16.
12. Li TS, Tubiana R, Katlama C, Calvez V, Ait MH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998 351 : 1682 6.
13. Hardy GA, Imami N, Sullivan AK et al. Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003 134 : 98 106.
14. Andre P, Groettrup M, Klenerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998 95 : 13120 4.
15. Chavan S, Kodoth S, Pahwa R, Pahwa S. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 2001 98 : 383 9.
16. Kelleher AD, Booth BL Sewell AK et al. Effects of retroviral protease inhibitors on the proteasome function and processing of HIV-derived MHC class I restricted cytotoxic T lymphocyte epitopes. AIDS Res Hum Retroviruses 2001 17 : 1063 6.
17. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001 11 : 87 98.
18. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999 341 : 1865 73.
19. Kroon FP, van Tol MJ, Jol-van der Zijde CM, van FR, van Dissel JT. Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol 1999 6 : 352 5.
20. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van FR. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995 21 : 1197 203.
21. Saikh KU, Sesno J, Brandler P, Ulrich RG. Are DNA-based vaccines useful for protection against secreted bacterial toxins? Tetanus toxin test case. Vaccine, 1998 16 : 1029 38.
22. Pontesilli O, Kerkhof-Garde S, Notermans DW et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999 180 : 76 86.
23. Rinaldo CR Liebmann JM, Huang XL et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999 179 : 329 36.